Clinical Scorecard: Decreased T2-ratio of right and left ventricular blood pools as a predictor of congestive heart failure following STEMI

At a Glance

Key Highlights

• CHF affects approximately 15% of patients within the first year after STEMI and significantly impacts survival and quality of life.
• Low RV/LV T2-ratio measured by CMR is associated with poor exercise capacity and may predict CHF development post-STEMI.
• The study used standardized CMR protocols including T2-mapping and late gadolinium enhancement to assess infarct characteristics and ventricular function.

Guideline-Based Recommendations

Diagnosis

• Use cardiac magnetic resonance imaging within the first week post-PCI to measure RV/LV blood pool T2-ratio.
• Assess infarct size, microvascular obstruction, and intramyocardial hemorrhage via late gadolinium enhancement and T2*-mapping.
• Define CHF as requiring intravenous diuretics or hospital readmission for heart failure symptoms during follow-up.

Management

• Primary PCI within 24 hours of symptom onset for first-time STEMI patients.
• Monitor patients with low RV/LV T2-ratio closely for early signs of CHF.
• Implement guideline-directed medical therapy for post-MI heart failure as indicated.

Monitoring & Follow-up

• Clinical follow-up at 4 and 12 months including questionnaire, physical exam, blood/urine analysis, echocardiography, and ECG.
• Telephonic follow-up beyond 400 days to assess major adverse cardiac events (MACE) including CHF, death, and re-infarction.
• Use T2-ratio dichotomized at the 10th percentile to stratify risk.

Risks

• CHF development post-STEMI is associated with increased mortality and morbidity.
• Low T2-ratio may indicate worse prognosis and higher risk of adverse cardiac events.
• Exclusion criteria for CMR include severe renal impairment, high Killip class, prior MI or coronary intervention, and contraindications to MRI or gadolinium.

Patient & Prescribing Data

First-time STEMI patients treated with primary PCI and undergoing CMR imaging

Early identification of patients with low RV/LV T2-ratio may guide intensified monitoring and management to prevent CHF progression.

Clinical Best Practices

• Perform CMR including T2-mapping within the first week after STEMI and PCI to evaluate ventricular blood pool T2-ratio.
• Exclude patients with contraindications to CMR or gadolinium contrast to ensure safety and data quality.
• Use standardized imaging protocols and software for volumetric and tissue characterization analyses.
• Incorporate T2-ratio assessment into risk stratification models for post-STEMI CHF prediction.
• Conduct comprehensive follow-up including clinical, laboratory, and imaging assessments to detect early CHF signs.

References

• European Society of Cardiology STEMI Guidelines
• MARINA-STEMI Study ClinicalTrials.gov NCT04113356
• Gadovist® Bayer Vital Product Information